- Home
- / Xiangxue Pharmaceutical
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Xiangxue Pharmaceutical financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
¥1.8 B
FY, 2024
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| CNY | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 2.3B | 2.7B | 2.9B | 2.9B | 2.1B | 2.2B | 1.8B |
| Cost of goods sold | 1.6B | 1.9B | 2.1B | 2.2B | 1.6B | 1.5B | 1.4B |
| Gross profit | 894.5M | 860.6M | 970.9M | 754.5M | 519.5M | 761.1M | 424.6M |
| Gross profit margin, % | 38.3% | 31.8% | 33.5% | 26.0% | 24.2% | 33.9% | 23.5% |
| Operating expense total | 566.0M | 547.3M | 650.6M | 627.3M | 435.1M | 415.4M | 389.6M |
| Depreciation and amortization | 120.9M | 114.8M | 586.0M | 392.3M | 322.1M | 545.6M | |
| EBITDA | 326.8M | 295.9M | 320.3M | 146.7M | 85.3M | 293.5M | 33.7M |
| EBITDA margin, % | 14.0% | 10.9% | 11.0% | 5.1% | 4.0% | 13.1% | 1.9% |
| EBIT | 213.0M | 213.5M | 269.8M | (464.4M) | (349.5M) | (96.8M) | (605.1M) |
| EBIT margin, % | 9.1% | 7.9% | 9.3% | -16.0% | -16.3% | -4.3% | -33.4% |
| Interest income | 6.3M | 4.2M | 5.1M | 8.3M | 3.9M | 1.2M | 2.8M |
| Interest expense | 145.7M | 150.7M | 130.3M | 202.1M | 213.2M | 237.1M | 232.9M |
| Pre tax profit | 112.0M | 117.1M | 166.1M | (635.8M) | (514.7M) | (389.0M) | (842.1M) |
| Income tax expense | 24.0M | (9.1M) | 24.3M | 22.9M | (6.8M) | 12.8M | 19.2M |
| Net Income | 88.0M | 126.1M | 141.8M | (658.7M) | (507.9M) | (401.7M) | (861.2M) |